Genmab shares jump as ovarian cancer drug shows durable responses in trial
Genmab's shares rose over 4% after its ovarian cancer drug, Rina-S, showed durable responses in a mid-stage trial. The study reported a 45.9% objective response rate and 9.5 months median progression-free survival. Genmab plans to advance Phase 3 trials. Common side effects included fatigue and nausea, with serious adverse events in about one-third of participants.
How this was made
The 30-second read
Why it matters
The data represent a material, first‑time disclosure that could shift valuation expectations for the company and its peers.
Market read
Positive trial data is a catalyst for biotech stocks, especially those in oncology, and may drive short‑term buying pressure.
What to watch
Long‑term commercial viability depends on Phase 3 outcomes and regulatory pathways.
Background
Genmab, a Danish biotech listed in the US as GMAB, disclosed mid‑stage trial results for its ovarian cancer candidate Rina‑S.
Ticker impact
Genmab reported durable responses and a 45.9% confirmed objective response rate in its Phase 1/2 ovarian cancer trial, prompting a >4% share jump.
upward pressure as the market prices in the efficacy data
First disclosure of trial results shows strong response rates and durability, a material catalyst for a biotech.
Market effects
Strengthens the oncology biotech sector, may boost peers developing folate‑receptor targeting agents.
European biotech markets could see modest gains on the back of the data.
Adds optimism to global cancer‑therapy pipelines, potentially influencing investor sentiment worldwide.
Counterpoint
Some investors may view the safety profile and modest PFS as insufficient for a major rally.
Key entities
- companyGenmab
Danish biotech developing Rina‑S for ovarian cancer.
- drug_candidateRina‑S
Experimental antibody‑drug conjugate targeting folate receptor alpha.
